A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.